Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-25 · accession 0001415889-24-027905 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-27 | 2024-11-25 | JANX | Campbell David Alan | Pres, CEO, Dir | S - Sale | $51.59 | -25.0K | 263.8K | -9% | -$1.29M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-25 | S | D | 6,719 | $52.04 | 257,054 | D | — | — | (F3) The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-11-25 | S | D | 18,281 | $51.43 | 263,773 | D | — | — | (F2) The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |